



### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

### RECEIVED

In re Application for:

JUN 1 9 2002

Charles A. NICOLETTE

Examiner: Not Yet Assigned TECH CENTER 1600/2900

Serial No.: 10/077,629

Group Art Unit: 1645

Filing Date: February 14, 2002

For: ALTERED PEPTIDE LIGANDS

#### INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents Washington, D.C. 20231

Dear Sir:

In accordance with 37 C.F.R. § 1.56, the references listed on the attached forms PTO-1449a and PTO-1449b are being brought to the attention of the Examiner for consideration in connection with the examination of the above-identified patent application. The Examiner is requested to make these documents of record.

1 nis	information	Disclosure	Statement is	s submiπea

- With the new patent application submitted herewith (37 C.F.R. § 1.97(a)).
- Within three months of the application filing date or before receipt of a first Office Action on the merits; accordingly, no fee or separate requirements are required.
- × Before the mailing date of the first Office Action on the merits. In the event, however that an Office Action has crossed in the mail with this Information Disclosure

Statement, the Commissioner is hereby authorized to charge Deposit Account
No. 50-1189 for any fees required pursuant to 37 C.F.R. §§ 1.17(p) or 1.17(i)(1).
After receipt of a first Office Action on the merits but before a final Office Action or
Notice of Allowance. A fee is required. The Commissioner is hereby authorized to
charge Deposit Account No. 50-1189 for any fees required pursuant to 37 C.F.R.
§§ 1.17(p) or 1.17(i)(1).
After receipt of a final Office Action or Notice of Allowance, but before payment of
the issue fee. Accordingly, a Certification under 37 C.F.R. § 1.97(e) is provided
herein. The Commissioner is hereby authorized to charge Deposit Account
No. 50-1189 for any fees required pursuant to 37 C.F.R. §§ 1.17(p) or 1.17(i)(1).
The undersigned certifies that:
Each item of information contained in the Information Disclosure Statement was first
cited in any communication mailed from a foreign patent office in a counterpart
foreign application not more than three months prior to the filing of this information
disclosure statement.
No item of information contained in this information disclosure statement was cited in
a communication mailed from a foreign patent office in a counterpart foreign
application or, to the knowledge of the undersigned after making reasonable inquiry,
was known to any individual designated in 37 C.F.R. § 1.56(c) more than three
months prior to the filing of this Information Disclosure Statement.

Applicants would appreciate the Examiner initialing and returning the Form PTO-1449, indicating that the information has been considered and made of record herein.

This Information Disclosure Statement under 37 C.F.R. § 1.97 is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols,

results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.

In the unlikely event that the transmittal letter is separated from this document and the U.S. Patent Office determines that an extension and/or other relief is required, applicant petitions for any required relief including extensions of time and authorizes the Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to Deposit Account No. 50-1178 referencing 19442-7250. However, the Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

Respectfully submitted,

Antoinette F. Konsk Registration No. 34,202

McCutchen Doyle Brown & Enersen LLP Three Embarcadero Center, Suite 1800 San Francisco, California 94111-4067

Telephone: (650) 849-4950 Facsimile: (650) 849-4800

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form1449A-PTO

Examiner's

Signature

JUN 1 7 2002 🕏

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet of

Complete if Known		
Application Number	10/077,629	
Filing Date	February 14, 2002	
First Named Inventor	Charles A. NICOLETTE	
Art Unit	1645	
Examiner Name	Not Yet Assigned	
Attorney Docket Number	GZ 2098.00	

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No.1	Document Number Number – Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YY	Name of Patentee or Application of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1	US-4,631,211	12-23-86	Houghton	Relevant Figures Appear
	2	US-5,101,175	04-23-91	Rutter et al.	RECEIVED
					JUN 1 9 2002
					TECH CENTER 1600/29

1

#### FOREIGN PATENT DOCUMENTS Examiner Cite Foreign Patent Document Publication Date Name of Patentee or Pages, Columns, Lines, No.1 Where Relevant Passages Initials\* Country Code3 - Number4 - Kind Code5 (if known) MM-DD-YY Application of Cited or Relevant Figures Appear Document WO 92/00252 01-09-92 TAS, Inc. Nicolette, Charles WO 97/35035 09-25-97

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609.	Draw line through citation if not in conformance and no
considered. Include conv.of this form with payt communication to applicant	

Date Considered

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to compete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Wathington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TC. Assistant Commissioner for Patents, Washington, D.C. 20231.

<sup>\*</sup>Applicants unique distant designation number (optional). \*See Kinde Coxtee of USPTO Platent Documents at <u>www.uspto.oo.g</u> or MPEP 901.04. \*Enter Office that issued the adoptional, by the hoselether roade (WIPC) Standard ST.3, \*For Apparence patent documents, the indication of the year of the proper proceed the serial number of the patent document. \*Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. \*Applicant is to place a check mark here if Registe in largue of the patent document. \*Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. \*Applicant is to place a check mark here if Registe in largue grant registers.

PTO/SB/08B (10-01)
Approved for USE through 10/31/2002, OMB 0851-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
ure required to respond to a collection of information unless it contains a valid CMB control number.

Substitute for form 1449B-PTO

Under the Paperwork Reduction Act of 1995, no person

型 JUN 1 7 2002

2

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

(		 	,	
Chast	-	 		

φ,ρ	.0.0 11 / 11 / 11 / 11
Application Number	10/077,629
Filing Date	February 14, 2002
First Named Inventor	Charles A. NICOLETTE
Art Unit	1645
Examiner Name	Not Yet Assigned
Attorney Docket Number	GZ 2098.00

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	-
Examiner	Cite	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal,	T <sup>2</sup>
Initials*	No.1	serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher city and/or country where published	1/2
	1	SINKOVICS, J.G. and HORVATH, J.C. "Vaccination against human cancers (review)" Int. J. Oncol. (2000)	
		16(1):81-96	
-	2 -	WEINER, L.M. "Monoclonal antibody therapy of cancer" Semin. Oncol. (October 1999) 26:43-51	_
	3	ROSELLI, M. et al. "Tumor markers as targets for selective diagnostic and therapeutic procedures" Anticancer Res.	1/2
	-	(1996) 16(4B):2187-2192	100
r	4 5	TRAIL, P.A. and BIANCHI, A.B. "Monoclonal antibody drug conjugates in the treatment of cancer" Cancer (1999)	۱ ۶
		11(5):584-588	
1	5 _	FAGERBERG, J. et al. "Human anti-idiotypic antibodies induced a humoral and cellular immune response against a	1
		colorectal carcinoma-associated antigen in patients" PNAS USA (May 1995) 92(11):4773-4777	
1	6	KAWAKAMI, Y. et al. "Cloning of the gene coding for a shared human melanoma antigen recognized by autologous	l
<b></b>		T cells infiltrating into tumor" PNAS USA (April 1994) 91(9):3515-3519	<u> </u>
ĺ	7 🕫	ENGLEHARD, V.H. "Structure of peptides associated with Class I and Class II MHC molecules" Annu. Rev.	ĺ
		Immunol. (1994) 12:181-207	
	8 5	RAMMENSEE, H-G. et.al. "Peptides naturally presented by MHC Class I molecules" Annu. Rev. Immunol. (1993)	
		11:213-244	├—
	9 ,	HUNT, D.F. et al. "Characterization of peptides bound to the Class I MHC molecule HLA-A2.1 by mass	
		spectrometry" Science (March 1992) 255:1261-1263	├
	10 _	UDAKA, K. et al. "A naturally occurring peptide recognized by alloreactive CD8* cytotoxic T lymphocytes in	
		association with a Class I MHC protein" Cell (June 1992) 69:989-998	-
	11	VAN DE WAL, Y. et al. "Small intestinal T cells of celiac disease patients recognize a natural pepsin fragment of gliadin" PNAS USA (August 1998) 95:10050-10054	
<b></b>	12	LAMB, J.R. et al. "A novel approach to the identification of T-cell epitopes in mycobacterium tuberculosis using	<del>  -</del>
	'2 -	human T-lymphocyte clones" immunology (1987) 60:1-5	1
h	13 =	BOON, T. et al. "Tumor antigens recognized by T lymphocytes" Annu. Rev. Immunol. (1994) 12:337-365	_
<b>——</b>	14	NEOPHYTOU, P.I. et al. "T-cell epitope analysis using subtracted expression libraries (TEASEL): application to a	<del>                                     </del>
	"-	38-kDa autoantigen recognized by T cells from an insulin-dependent diabetic patient" PNAS USA (March 1996)	
1		93:2014-2018	
	15	GAVIN, M.A. et al. "Major histocompatibility complex class I allele-specific peptide libraries: identification of	
	-	peptides that mimic an H-Y T cell epitope" Eur. J. Immunol. (1994) 24:2124-2133	l
	16 .	GUNDLACH, B.R. et al. "Determination of T cell epitopes with random peptide libraries" J. Immunol. Meth. (1996)	
		192:149-155	
	17 👡	BLAKE, J. et al. "Use of combinatorial peptide libraries to construct functional mimics of tumor epitopes recognized	
		by MHC Class I-restricted cytolytic T lymphocytes" J. Exp. Med. (July 1996) 184:121-130	
	18 -	HIEMSTRA, H.S. et al. "The identification of CD4* T cell epitopes with dedicated synthetic peptide libraries" PNAS	
		USA (September 1997) 94:10313-10318	
	19	HEMMER, B. et al. "Identification of high potency microbial and self ligands for a human autoreactive Class II-	
		restricted T cell clone" J. Exp. Med. (May 1997) 185(9):1651-1659	<u> </u>
	20	CHEN, Y-Z. et al. "Response of a human T cell clone to a large panel of altered peptide ligands carrying single	1
		residue substitutions in a antigenic peptide" J. Immunol. (1996) 157:3783-3790	<u> </u>
1	21 _	STRAUSBAUCH, M.A. et al. "Identification of mimotopes for the H4 minor histocompatibility antigen" Intl. Immunol.	1
L	L	(1998) 10(4):421-434	L

		Sheet 2 of Attorney Docket Nober GZ 2098.00	
l		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Examiner	Cite	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal,	T <sup>2</sup>
Initials*	No.1	serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher city and/or country where published	'
VE	22	VALMORI, D. et al. "Induction of potent antitumor CTL responses by recombinant vaccinia encoding a melan-A	十一
112 0	V"-	peptide analogue" J. Immunol. (2000) 164(2):1125-1131	
	30 -	McMAHAN, C.J. and FINK, P.J. "Receptor revision in peripheral T cells creates a diverse Vβ repertoire" J. Immunol.	├
1 200	1 5	(2000) 165:6902-6907	1
10H 1 7 700	製	KUSAKA, S. et al. "Clonotype analysis of human alloreactive T cells; a novel approach to studying peripheral	+-
	* -	tolerance in a transplant recipient" J. Immunol. (2000) 164:2240-2247	1
& TRAUE	25	KALERGIS, A.M. et al. "Single amino acid replacements in an antigenic peptide are sufficient to alter the TOCAS	Y/Z
		repertoire of the responding CD8* cytotoxic lymphocyte population" J. Immunol. (1999) 162:7263-7270	2
	26	CHICZ, R.M. and URBAN, R.G. "Analysis of MHC-presented peptides: applications in autoimmunity and vaccines."	-
	_	development" Immunol. Today (1994) 15(4):155-160	Į.
	27 ~	SCOTT, J.K. and SMITH, G.P. "Searching for peptide ligands with an epitope library" Science (1990) 249:386-390	b
	28	CWIRLA, S.E. et al. "Peptides on phage: a vast library of peptides for identifying ligands" PNAS USA (August	62
		1990) 87:6378-6382	12
	29_	DEVLIN, J.J. et al. "Random peptide libraries: a source of specific protein binding molecules" Science (1990)	13
		249:404-406	2
	30	GEYSEN, H.M. et al. "A priori delineation of a peptide which mimics a discontinuous antigenic determinant" Mol.	
	_	Immunol. (1986) 23(7):709-715	
	31	GEYSEN, H.M. et al. "Strategies for epitope analysis using peptide synthesis" J. Immunol. Meth. (1987) 102:259-	
		274	<u></u>
	32_	FODOR, S.P.A. et al. "Light-directed, spatially addressable parallel chemical synthesis" Science (February 1991)	J
		251:767-773	
	33	FURKA, Á. et al. "Cornucopia of Peptides by Synthesis" 14th Int'l Congress of Biochemistry (1988) Vol 5, Abst.	ł
<u> </u>		FR:013	_
	34 _	FURKA, A. et al. "General method for rapid synthesis of multicomponent peptide mixtures" Int. J. Peptide Protein	
	35	Res. (1991) 37:487-493  NEEDELS, M.C. et al. "Generation and screening of an oligonucleotide-encoded synthetic peptide library" PNAS	
	35	USA (November 1993) 90:10700-10704	]
	36	OHLMEYER, M.H.J. et al. "Complex synthetic chemical libraries indexed with molecular tags" PNAS USA	-
	"	(December 1993) 90:10922-10926	1
	37	HEDRICK, S.M. et al. "Isolation of cDNA clones encoding T cell-specific membrane-associated proteins" Nature	
		(March 1984) 308:149-153	
	38	LIANG, P. and PARDEE, A.B. "Differential display of eukaryotic messenger RNA by means of the polymerase chain	
		reaction" Science (August 1992) 257:967-971	
	39	ADAMS, M.D. et al. "Complementary DNA sequencing: expressed sequence tags and human genome project"	
		Science (June 1991) 252:1651-1656	
	40	ALWINE, J.C. et al. "Method for detection of specific RNAs in agarose gels by transfer to diazobenzyloxymethyl-	_
		paper and hybridization with DNA probes" PNAS USA (December 1977) 74:5350-5354	
	41	ZINN, K. et al. "Identification of two distinct regulatory regions adjacent to the human β-interferon gene" Cell	
		(October 1983) 34:865-879	<u> </u>
	42	VERES, G. et al. "The molecular basis of the sparse fur mouse mutation" Science (July 1987) 237:415-417	
	43	VAN DER ZEE, R. et al. "Efficient mapping and characterization of a T cell epitope by the simultaneous synthesis of	
		multiple peptides" Eur. J. Immunol. (1989) 19:43-47	
			-
	1		1

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Date

Considered

Examiner's

Signature

<sup>&</sup>lt;sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

A Spliciant's disease users used users using season and users of the season an